Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients, \>=18 years of age;
breast cancer with measurable locally recurrent or metastatic lesions;
candidate for chemotherapy;
HER2-positive disease;
ECOG PS of \<=2.
You may not be if
previous anticancer therapy for metastatic breast cancer;
previous radiotherapy for metastatic breast cancer (except for adjuvant radiotherapy \>=6 months before enrollment);
chronic daily treatment with corticosteroids (\>=10mg/day), aspirin (\>325 mg/day) or clopidogrel (\>75mg/day);
other primary tumor within last 5 years, except for adequately treated cervical cancer in situ, squamous or basal cell skin cancer;
uncontrolled hypertension or significant cardiovascular disease.
Clareo Health | A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer
